[1] Sharma P,Sawtell R,Wang Q,et al. Management of hepatitis C virus and hepatitis B virus infection in the setting of kidney disease[J]. Adv Kidney Dis Health,2023,30(2):343-355.
[2] Gupta A,Quigg R J. Glomerular diseases associated with hepatitis B and C[J]. Adv Chronic Kidney Dis,2015,22(5):343-351.
[3] Noris M, Daina E, Remuzzi G, et al. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment[J]. Nephrol Dial Transplant,2023,38(2):283-290.
[4] Chen Y, Yang X, Feng M, et al. Exosomal miR223-3p from bone marrow mesenchymal stem cells targets HDAC2 to downregulate STAT3 phosphorylation to alleviate HBx-induced ferroptosis in podocytes[J]. Front Pharmacol,2024,15(2):130-136.
[5] Deng C L,Song X W,Liang H J, et al.Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells[J]. World J Gastroenterol,2006,12(11):1752-1756.
[6] Ren J, Wang L, Chen Z,et al.Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy[J]. J Med Virol,2006,78(5):551-560.
[7] Fabrizi F, Dixit V, Martin P, et al. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis[J]. Aliment Pharmacol Ther,2006,24(5):781-788.
[8] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int,2024,105(4S):S117-S314.
[9] Zhang Y, Zhou J,Yin X L,et al.Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis[J]. World J Gastroenterol,2010,16(6):770-776.
[10] Fu B, Ji Y, Hu S, Ren T, et al.Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis[J].PLoS One,2020,15(1):210-226.
[11] Li Y, Yang S, Li C, et al. Efficacy of short-term Peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study[J]. Virol J,2024,21(1):231-236.
[12] Li T, Ke Z, Liu W, et al.Human hepatitis B virus core protein inhibits IFNα-induced IFITM1 expression by interacting with BAF200[J]. Viruses, 2019,11(5):427-438.
[13] Lin C Y. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon[J]. Kidney Int,1995,47(1):225-230.
[14] Chung D R, Yang W S, Kim S B, et al. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon[J]. Am J Nephrol,1997,17(2):112-117.
[15] Shah H,Patel C,Jhaveri K D,et al.Complete remission of hepatitis B virus-associated nephrotic syndrome from IgA nephropathy following peginterferon therapy[J]. Ren Fail,2013,35(2):295-298.
[16] Lopes E P,Lopes L V,Kirsztajin G M, et al.Alpha-interferon therapy for HBV-related glomerulonephritis[J]. Sao Paulo Med J, 1998,116(5):1823-1825.
[17] Wang L,Ye Z,Liang H,et al.The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication[J], Am J Transl Res, 2016,8(3):1593-1600.
[18] Wang L, Xie B, Zheng Q, et al. Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy[J]. Rev Esp Enferm Dig,2020,112(11):843-849.
[19] Yu Y, Xu L, Xu T, et al. Efficacy and safety of entecavir for hepatitis B virus-associated glomerulonephritis with renal insufciency[J]. Clin Exp Nephrol,2023,27(3):680-686.
[20] Zhao W. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (text extract): executive summary[J]. Infect Dis Immun,2024,4(3):103-105.
[21] Matthews S J. Entecavir for the treatment of chronic hepatitis B virus infection[J]. Clin Ther,2006,28(2):184-203.
[22] Foucault T, Handala L, Paintaud G, et al. Treatment of chronic hepatitis B: virological and pharmacologi cal aspects[J]. Virologie, 2022,26(3):228-239.
[23] Fischer M G, Newman W, Hammer K, et al. A systematic review assessing the potential use of cystatin C as a biomarker for kidney disease in people living with HIV on antiretroviral therapy[J]. Front Med Pract, 2024,19(11):267-273.
[24] Farag M S, Fung S, Tam E, et al. Effectiveness and renal safety of tenofovir alafenamide fuma rate among chronic hepatitis b patients: real-world study[J]. J Viral Hepat,2021,28(6):942-950.
[25] Hosaka T, Suzuki F, Kobayashi M, et al. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B[J]. Hepatol Res,2022,52(2):153-164.
[26] Lgarashi T, Shimizu A, Igarashi T, et al. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy[J]. J Nippon Med Sch,2013,80(5):387-395.
[27] Mweemba A, Zanolini A, Mulenga L, et al.Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults[J]. Clin Infect Dis,2014,59(12):1757-1760.
[28] Geragotellis A, Patel S, Sonderup M, et al. Tenofovir alafenamide: an initial experience at groote schuur hospital, Cape Town, South Africa[J]. S Afr Med J,2020,112(2):113-116.
[29] Mweemba A, Zanolini A, Mulenga L, et al. Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults[J]. Clin Infect Dis,2014,59(12):1757-1760.
[30] 王晓玲,郝金翠,王春燕,等.趋化因子 RANTES、IL-17以及TGF-β1在HBV-GN患者应用激素及免疫抑制剂的趋势研究[J].中国免疫学杂志,2018,34(10):1537-1541. |
